Halozyme Therapeutics

Halozyme Therapeutics

HALO· Manufacturing· Market cap · Fiscal year ends in December

CEO pay in FY2025Stock +40.8% in FY2025

Helen I. Torley is the CEO of Halozyme Therapeutics and was paid $23.2M in FY2025 (Dec), up 82%.

Pay$100 in the stock at the end of FY20 → $158
CEO pay is from each Halozyme Therapeutics proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Executives5

See all
  1. 1Helen I. TorleyFY2025
  2. 2Nicole LaBrosseFY2025
  3. 3Mark SnyderFY2025
  4. 4Cortney CaudillFY2025
  5. 5Michael J. LaBarreFY2025

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

Pay

See all

Halozyme Therapeutics paid its 5 named executives $37.5M in total in FY2025 (Dec). CEO Helen I. Torley was paid $23.2M of that.

Name
Helen I. TorleyPresident and Chief Executive Officer
Nicole LaBrosseSenior Vice President, Chief Financial Officer
Mark SnyderSenior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary
Cortney CaudillSenior Vice President, Chief Operating OfficerNot disclosedNot disclosed
Michael J. LaBarreFormer Senior Vice President, Chief Technical Officer

of each named executive, from the Summary Compensation Table of each proxy.

Peers18

See all

The FY2025 (Dec) proxy of Halozyme Therapeutics names 18 peer companies for pay. Among Halozyme Therapeutics and these peers, CEO pay was 3rd highest of 9 and total shareholder return was 4th highest of 9.

3rd highest of 9in Halozyme Therapeutics and its pay peers, FY2025 (Dec) by CEO pay:

$6.9M$33.2M

4th highest of 9in Halozyme Therapeutics and its pay peers, FY2025 (Dec) by total shareholder return:

$68$523

The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.

Board2

See all
  • Jeffrey W. HendersonChair · 10 yr on the boardIndependentAudit—Paid as an executive
  • Mahesh KrishnanDirector · 1 yr on the boardIndependentCompensation, Nominating and Corporate Governance—Paid as an executive

The board of the latest proxy (FY2025).

Activity

  1. Pay
    Halozyme Therapeutics Former Senior Vice President, Chief Technical Officer pay fell 32% to $2.1M. The stock rose 41% in FY2025 (Dec).
    DEF 14A
  2. Pay
    Halozyme Therapeutics General counsel pay fell 16% to $4.5M. The stock rose 41% in FY2025 (Dec).
    DEF 14A
  3. Pay
    Halozyme Therapeutics CEO pay rose 82% to $23.2M. The stock rose 41% in FY2025 (Dec).
    DEF 14A
  4. Board
    Mahesh Krishnan joined the board of Halozyme Therapeutics. Mahesh Krishnan sits on no other public board.
    3
  5. Pay
    Halozyme Therapeutics General counsel pay rose 49% to $5.4M. The stock rose 29% in FY2024 (Dec).
    DEF 14A
  6. Pay
    Halozyme Therapeutics CFO pay rose 43% to $3.8M. The stock fell 35% in FY2023 (Dec).
    DEF 14A
  7. Pay
    Halozyme Therapeutics Former Senior Vice President, Chief Technical Officer pay rose 37% to $3.1M. The stock rose 42% in FY2022 (Dec).
    DEF 14A
  8. Pay
    Halozyme Therapeutics CEO pay rose 22% to $11.8M. The stock fell 35% in FY2023 (Dec).
    DEF 14A
  9. Pay
    Halozyme Therapeutics CEO pay rose 30% to $9.7M. The stock rose 42% in FY2022 (Dec).
    DEF 14A

Filings6

See all
Proxy statementDEF 14AMar 23, 2026FY2025
Annual report10-KFeb 17, 2026FY2025
Proxy statementDEF 14AMar 18, 2025FY2024
Annual report10-KFeb 18, 2025FY2024
Proxy statementDEF 14AMar 15, 2024FY2023
Annual report10-KFeb 20, 2024FY2023
For the press:Download CSVDownload PNGHow to use our data